Covaxin neutralises multiple coronavirus variants, says ICMR
Covaxin has been developed by Hyderabad-based Bharat Biotech in collaboration with the CMR-National Institute of Virology.
April 21, 2021 / 03:24 PM IST
File image of the Covaxin COVID-19 vaccine
Covaxin, Bharat Biotech's COVID-19 vaccine, is effective against multiple coronavirus variants, including the double mutant strain, according to a study by the Indian Council of Medical Research (ICMR).
"ICMR study shows COVAXIN neutralises against multiple variants of SARS-CoV-2 and effectively neutralises the double mutant strain as well," ICMR said in a tweet.
Also read: Bharat Biotech Covaxin demonstrates 78% efficacy in Phase-3 interim analysis
Covaxin has been developed by Hyderabad-based Bharat Biotech in collaboration with the ICMR-National Institute of Virology.
ICMR-NIV has successfully isolated and cultured multiple variants of concern of SARS-CoV-2 virus - B.1.1.7 (the UK variant), B.1.1.28 (Brazil variant ) and B.1.351 (South Africa variant).
ICMR-NIV has demonstrated the neutralisation potential of Covaxin against the UK variant and Brazil variants, the apex health research body said.
In a subsequent statement, Bharat Biotech said phase 3 interim analysis results of Covaxin demonstrated that the vaccine has 78 percent efficacy.